Are current ICER thresholds outdated? Valuing medicines in the era of personalized healthcare

Pricivel Carrera; Maarten J IJzerman

doi:10.1080/14737167.2016.1180980

Are current ICER thresholds outdated? Valuing medicines in the era of personalized healthcare

Expert Rev Pharmacoecon Outcomes Res. 2016 Aug;16(4):435-7. doi: 10.1080/14737167.2016.1180980. Epub 2016 May 6.

Authors

Pricivel Carrera¹, Maarten J IJzerman¹

Affiliation

¹ a Health Technology and Services Research , University of Twente , Enschede , The Netherlands.

PMID: 27118144
DOI: 10.1080/14737167.2016.1180980

No abstract available

Keywords: Multiple criteria decision analysis; cost-effectiveness; drug reimbursement; health technology assessment; personalized health care; value-based pricing.

Publication types

Editorial

MeSH terms

Antineoplastic Agents / economics
Cost-Benefit Analysis
Humans
Orphan Drug Production / economics
Pharmaceutical Preparations / economics*
Precision Medicine / methods*
Technology Assessment, Biomedical / methods*

Substances

Antineoplastic Agents
Pharmaceutical Preparations